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Abstract
Childhood sarcoidosis is a rare multisystemic granulomatous disorder of unknown etiology. In the
pediatric series reported from the southeastern United States, sarcoidosis had a higher incidence
among African Americans. Most reported childhood cases have occurred in patients aged 13–15
years. Macrophages bearing an increased expression of major histocompatibility class (MHC) II
molecules most likely initiate the inflammatory response of sarcoidosis by presenting an
unidentified antigen to CD4+ Th (helper-inducer) lymphocytes. A persistent, poorly degradable
antigen driven cell-mediated immune response leads to a cytokine cascade, to granuloma
formation, and eventually to fibrosis. Frequently observed immunologic features include depression
of cutaneous delayed-type hypersensitivity and a heightened helper T cell type 1 (Th1) immune
response at sites of disease. Circulating immune complexes, along with signs of B cell hyperactivity,
may also be found. The clinical presentation can vary greatly depending upon the organs involved
and age of the patient. Two distinct forms of sarcoidosis exist in children. Older children usually
present with a multisystem disease similar to the adult manifestations, with frequent hilar
lymphadenopathy and pulmonary infiltrations. Early-onset sarcoidosis is a unique form of the
disease characterized by the triad of rash, uveitis, and arthritis in children presenting before four
years of age. The diagnosis of sarcoidosis is confirmed by demonstrating a typical noncaseating
granuloma on a biopsy specimen. Other granulmatous diseases should be reasonably excluded. The
current therapy of choice for sarcoidosis in children with multisystem involvement is oral
corticosteroids. Methotrexate given orally in low doses has been effective, safe and steroid sparing
in some patients. Alternative immunosuppressive agents, such as azathioprine, cyclophosphamide,
chlorambucil, and cyclosporine, have been tried in adult cases of sarcoidosis with questionable
efficacy. The high toxicity profile of these agents, including an increased risk of lymphoproliferative
disorders and carcinomas, has limited their use to patients with severe disease refractory to other
agents. Successful steroid sparing treatment with mycophenolate mofetil was described in an
adolescent with renal-limited sarcoidosis complicated by renal failure. Novel treatment strategies
for sarcoidosis have been developed including the use of TNF-alpha inhibitors, such as infliximab.
The long-term course and prognosis is not well established in childhood sarcoidosis, but it appears
to be poorer in early-onset disease.
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Introduction
Sarcoidosis is a multisystem systemic granulomatous dis-
ease of unknown etiology that most commonly affects
young adults, who frequently present with hilar lymphad-
enopathy, pulmonary infiltration, and ocular and cutane-
ous lesions [1]. Although the lung is most frequently
involved, the disease can affect any organ system of the
body [2]. The disease is relatively rare in the pediatric pop-
ulation [3,4]. Infants and children younger than 5 years
usually present with the triad of skin, joint, and eye
involvement, without typical lung disease. However,
older children have involvement of the lungs, lymph
nodes, and eyes more frequently, as seen in adult [5,6].
Despite a variety of hypotheses regarding causative agents,
the cause of sarcoidosis is unknown [7]. The definitive
diagnosis of sarcoidosis is made when compatible clinical
findings are associated with histopathological evidence of
noncaseating granulomata in affected organs and other
granulomatous disorders are excluded [8]. The illness can
be self-limited or chronic, and the disease characteristics
vary among various populations [1]. The course and prog-
nosis of sarcoidosis in children is different compared to
adults, and may correlate with the mode of onset and the
extent of the disease [1,9,10].
In this review, we discuss the epidemiology, pathogenesis,
etiology, and clinical features of sarcoidosis in children,
and examine the current approaches to diagnosis and
treatment of this enigmatic disease.
Epidemiology
The prevalence of sarcoidosis in the adult population
ranges from 10 to 40 per 100,000 in the United States and
Europe [1]. The true incidence and prevalence of child-
hood sarcoidosis is unknown because of the rarity of the
disease and the small number of reported cases in child-
hood. A recent review reported that the approximate inci-
dence of clinically recognized sarcoidosis in Danish
children younger than 15 years was 0.22–0.27 per
100,000 children per year, corresponding to approxi-
mately 3 new cases in Denmark each year [4]. As in adults,
many children with sarcoidosis may be asymptomatic and
the disease may remain undiagnosed.
Most reported childhood cases have occurred in patients
aged 13–15 years [11,12]. In a recent international registry
study of childhood sarcoidosis associated with joint
involvement, the mean age at onset was 10.6 years (range,
0.1–16 years) [13]. Early-onset childhood sarcoidosis (ie,
with onset in the first 4 y of life) is rare but well described
[5,6].
Adult studies have reported a slightly higher disease rate
for women. A population-based study of incidence and
survival in adults with sarcoidosis reported incidence rates
of 5.9 per 100,000 person-years for men and 6.3 per
100,000 person-years for women. No clear sex predomi-
nance exists in childhood sarcoidosis. In a recent study
from Denmark, the male/female gender ratio was close to
one [4].
The racial distribution of sarcoidosis varies with geo-
graphic location. In the US adult population, sarcoidosis
occurs in about 35.5 per 100,000 blacks and 11 per
100,000 whites. Studies in military and veteran popula-
tions showed that blacks are 10–17 times more com-
monly affected with sarcoidosis than are whites [1]. In the
pediatric series reported from the southeastern United
States, sarcoidosis had a higher incidence among African
Americans [11,14]. In children aged 4 years and younger
with sarcoidosis, 7–28% are African Americans, whereas
in children aged 8–15 years, the percentage of African
Americans increases to 72–81% [5,11,14]. Outside the
United States, sarcoidosis most frequently occurs in the
predominant race of the country. Thus, in Scandinavian
countries where sarcoidosis is common, almost all cases
occur in white people, while in Japan, most patients are
Asian [1,15].
Within the US, approximately 80% of childhood cases
have been reported primarily in Virginia, North Carolina,
South Carolina, and Arkansas, and Louisiana, suggesting
that the southeastern and south central states are an
endemic area for childhood sarcoidosis [11,14,16,17].
Genetics of sarcoidosis
Familial aggregation and the striking racial variation in
sarcoidosis incidence suggest a genetic predisposition to
develop sarcoidosis [18]. The strongest support for a
genetic susceptibility to sarcoidosis comes from numer-
ous reports of familial clustering of cases [19,20]. In the
United States, familial clusters more frequently are
observed in African Americans, with a rate of at least 19%
in affected African American families as compared to 5%
in white families. When sarcoidosis has been observed in
twins, monozygotic twins are 2–4 times more concordant
for disease than dizygotic twins [19]. The most common
familial relationship is sibling pairs, followed by parent-
offspring [19]. The hereditary differences in candidate
genes that promote susceptibility may reside in loci that
influence regulation of antigen presentation or recogni-
tion, T cell function, or the regulation of matrix deposi-
tion that favors granuloma formation and progressive
fibrosis.
Genetic factors may also be important in defining the pat-
tern of disease presentation, its severity, and prognosis.
Several investigators have searched for associations with
human leukocyte antigen (HLA)-related genes that mayPediatric Rheumatology 2008, 6:16 http://www.ped-rheum.com/content/6/1/16
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confer susceptibility to sarcoidosis [21]. A genome-wide
linkage analysis performed in German families with fol-
low-up fine mapping studies has revealed a unique candi-
date gene, BTNL2 in the MHC II region on chromosome
6 [22]. A follow-up study found that sarcoidosis is associ-
ated with a truncating splice site mutation in BTNL2 [23].
The BTNL2-conferred sarcoidosis risk has been noted in
both Caucasians and African-Americans [24]. A genome-
wide scan performed in African-American families with
follow-up fine mapping studies has indicated chromo-
some 5 as potentially harboring candidate genes [25].
Etiology
Despite the global occurrence of sarcoidosis, the etiology
of sarcoidosis is unknown. Most experts think that sar-
coidosis results from exposure of genetically susceptible
hosts to specific environmental, occupational or infec-
tious agents that trigger an exaggerated cellular immune
response, leading to granuloma formation [20,26].
Despite extensive research, no defined cause has been
demonstrated to account for the granulomata that charac-
terize the disease [26-28].
Case clustering, and immunologic and clinical similarities
of sarcoidosis to infectious granulomatous diseases sug-
gests that an infectious agent may be responsible. Myco-
bacteria, including Mycobacterium tuberculosis and other
atypical species have received the greatest amount of
attention [29-32]. The detection of mycobacterial DNA in
sarcoid lesions by polymerase chain reaction (PCR) lends
support to that association [32]. A recent molecular study
identified a novel candidate tissue antigen of mycobacte-
rial origin, the Mycobacterium tuberculosis catalase-per-
oxidase protein (mKatG) in sarcoid granulomas as a
potential target of the adaptive immune response in sar-
coidosis [31].
Besides Mycobacteria, many different antigens are under
suspicion, including other bacteria such as Proprionibacte-
rium acnes [32]. However, results from different studies
have varied considerably and have failed in their attempts
to fulfill the Koch postulates. Therefore the role of myco-
bacteria and proprionibacteria in the pathogenesis of sar-
coidosis remains a controversial issue [33]. Recent report
by Izbicki and colleagues revealed increase incidence of
sarcoidosis among fire fighters in NY City that were
involved in the 2001 disaster. This suggests that exposure
to world trade center "dust" may play a role in sarcoidosis
etiology [34].
Immunopathogenesis
Sarcoidosis is a chronic inflammatory disease character-
ized by a highly focused exaggerated immune response to
an unknown antigen(s) at the target organs. The hall-
marks of the disease, sarcoid granulomas, most likely are
formed in response to a persistent, poorly degradable,
antigenic stimulus [1]. Macrophages, bearing increased
expression of major histocompatibility class (MHC) II
molecules, most likely initiate the inflammatory response
of sarcoidosis by presenting an unidentified antigen to
CD4+ Th (helper-inducer) lymphocytes. This results in
proliferation and activation of the T cell [35].
The immunopathology has been best studied in broncho-
alveolar lavage fluid and lung disease in which early
lesions consist of an alveolitis with a high proportion of
activated CD4+ Th1 cells, which may precede granuloma
formation [1,36]. CD4+ and CD8+ T-lymphocytes, as well
as a few B-lymphocytes, form a characteristic ring at gran-
uloma periphery [37]. Most granuloma-associated lym-
phocytes have a Th1 phenotype, secreting cytokines,
including interferon gamma, interleukin (IL) -2, IL-12,
and tumor necrosis factor-alpha (TNF-α), which is likely
to favor the granulomatous response at sites of disease
activity [38]. Additionally, alveolar macrophages release a
variety of cytokines, including TNF-alpha, IL-1, IL-6, IL-
12, IL-15, and growth factors in patients with sarcoidosis
and pulmonary disease [35,37]. IL-18, a monocyte/mac-
rophage-derived cytokine has been recently identified as
an IFN-gamma-inducing factor and plays an important
role in the induction of Th1 response and sarcoid granu-
loma formation [39].
Chemokines may play an important role in the pathogen-
esis of sarcoidosis [35]. Chemokine receptors, CXCR3 and
CXCR6 are co-expressed by Th1 cells infiltrating the lung
and the granuloma of patients with sarcoidosis [40].
Recent data show that T cells expressing CCR6, CXCR3,
and CXCR6 act coordinately with respective ligands and
Th1 inflammatory cytokines in the alveolitic/granuloma
phases of the disease [41].
The CD4+ lymphocytes, in association with other
immune effector cells, such as macrophages, mast cells,
and natural killer cells, perpetuate the inflammatory
response by release of cytokines, monocyte chemotactic
factors, macrophage migration inhibitory factor, leuko-
cyte inhibitory factor, adhesion molecules (CD49a,
CD54, CD102), and growth factors [35,36].
As a result of these various immunologic interactions, an
acute and often a chronic cascade of inflammation occur.
This is characterized by changes in tissue permeability,
cellular influx, and local cell proliferation, resulting in a
granuloma. Persistent antigenic stimulation is believed to
maintain the pathogenic processes. Sarcoid granulomas
either resolve or heal by fibrosis. Genetic polymorphisms
may influence the clinical expression of sarcoid granu-
loma and disease outcome [35].Pediatric Rheumatology 2008, 6:16 http://www.ped-rheum.com/content/6/1/16
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Other immunologic abnormalities observed in patients
with sarcoidosis include circulating immune complexes,
B-cell hyperactivity, spontaneous in situ production of
immunoglobulins, and depression of cutaneous delayed-
type hypersensitivity reactions [1].
Clinical manifestations
Because sarcoidosis is a multisystem disease and affects
most organs, the clinical presentation can vary greatly. In
most children, the disease frequently involves the lungs,
lymph nodes, eyes, skin, liver, and spleen [4,7,9]. Most of
the reported cases of childhood sarcoidosis are accompa-
nied by nonspecific constitutional symptoms, such as
fever, fatigue, malaise, and weight loss, as well as symp-
toms from particular organs such as lungs, eyes, skin, and
lymph nodes. [4,9,14,15]. The disease can be asympto-
matic in children and remain undiagnosed [4].
Two distinct forms of childhood sarcoidosis appear to
exist. Older children usually present with a multisystem
disease similar to the adult manifestation with frequent
lymphadenopathy and pulmonary involvement, as well
as generalized signs and symptoms, such as fever, malaise,
and weight loss [4,13-15]. In contrast, early-onset child-
hood sarcoidosis is a unique form of the disease character-
ized by the triad of rash, uveitis, and arthritis in children
who are younger than 5 years [5,6,10].
Pulmonary manifestations
The lung is the organ most commonly involved in sar-
coidosis [1,2,7]. Pulmonary symptoms are usually mild
and often consist of a dry hacking cough, with or without
mild to moderate dyspnea, and occasionally chest pain
[15]. Physical examination is often unremarkable, but
crackles, ronchi, wheezing, or diminished breath sounds
may be noted. Bilateral hilar lymphadenopathy with or
without parenchymal involvement is the most common
radiographic finding [4,42] (Figures 1). Typically, the
hilar lymphadenopathy is symmetrical, although in rare
instances it may appear unilateral. Parenchymal involve-
ment is usually an interstitial pattern, although nodular,
alveolar, and fibrotic patterns also are described [42] (Fig-
ure 2).
In a recent Danish study, chest radiographs were normal
(stage 0) in 10%; 71% had isolated bilateral hilar lym-
phadenopathy (stage I), 8.3% had bilateral hilar adenop-
athy with pulmonary infiltrates (stage II) and 8.3% had
parenchymal infiltrates without hilar adenopathy (stage
III). None of the 48 reported patients had evidence of
fibrosis (stage IV) [4].
Nearly half of all children with sarcoidosis demonstrate
restrictive lung disease on static and dynamic pulmonary
function tests [4,7,11,43]. These changes are nonspecific
and believed to be secondary to the early alveolitis pro-
gressing to fibrosis. Obstructive ventilatory defects sec-
ondary to intrabronchial sarcoid granuloma or hilar/
Chest radiograph in a 10-year-old female with sarcoidosis  showing hilar adenopathy Figure 1
Chest radiograph in a 10-year-old female with sar-
coidosis showing hilar adenopathy.
Pulmonary infiltrates of sarcoidosis: Chest radiograph in a  12-year-old female with sarcoidosis showing patchy, diffuse  alveolar infiltrates involving both lungs (Left) Figure 2
Pulmonary infiltrates of sarcoidosis: Chest radio-
graph in a 12-year-old female with sarcoidosis show-
ing patchy, diffuse alveolar infiltrates involving both 
lungs (Left). A repeated study 6 months later with signifi-
cant improvement (Right).Pediatric Rheumatology 2008, 6:16 http://www.ped-rheum.com/content/6/1/16
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mediastinal lymph node compression of the airways or
bronchiectasis may be occasionally seen [11,15,43].
Reticuloendothelial System
The most common physical sign of reticuloendothelial
involvement is peripheral lymph node enlargement noted
in 40% to 70% of cases [4,11,14], which is also the most
accessible site for diagnostic biopsy [15]. Lymph nodes
are typically firm, non-tender, and freely movable.
Although hepatosplenomegaly may occur in up to 43% of
patients with childhood sarcoidosis [11], clinical manifes-
tations are not as apparent [9].
Ocular manifestations
Ocular involvement is common in childhood sarcoidosis.
Visual symptoms such as eye pain, blurry vision, photo-
phobia, and redness may be present in 29% of the
patients [4,44]. Anterior segment disease consisting of
uveitis or iritis is the most common manifestation occur-
ring in 24% to 58% of the children with sarcoidosis
[4,6,9,11,13,15]. Uveitis of sarcoidosis is characterized by
firmly-edged keratic precipitates, most commonly
develop in the lower part of the cornea and also seen in
the limbus; iris nodules; and focal synechiae related to
nodule formation. However, the majority of the synechiae
are caused by adhesions between iris and lens due to
inflammation [11]. Chorioidal granuloma and peripheral
multifocalchorioiditis are very specific for ocular sar-
coidosis. Conjunctival granulomas are the second most
common ocular manifestation in sarcoidosis and may
appear as tiny, translucent, pale yellow nodules [44].
Other ocular lesions can include keratitis, retinitis, glau-
coma, and involvement of the eyelids and lacrimal glands
[44]. Ophthalmological slit lamp examination is manda-
tory in the evaluation of childhood sarcoidosis [9]. If left
untreated, serious complications including blindness can
occur [6,10,13].
Skin manifestations
An erythematous rash is commonly noted in childhood
sarcoidosis and occurs in 77% of young children and 24–
40% in older children [4,5,11,14] (Figure 3). The most
frequent cutaneous eruptions include soft, red to yellow-
ish brown, or violaceous, flat-topped papules, found most
frequently on the face [3]. In children, macular lesions
with scarring and ichthyosiform cutaneous manifesta-
tions are frequently encountered [45]. Larger, violaceous,
plaque-like lesions may be found on the trunk, extremi-
ties, and buttocks. In a recent study, erythema nodosum
was noted in 31% of the children [4]. Other skin lesions
of sarcoidosis include nodules, hyperpigmented or hypo-
pigmented lesions, ulcers, and subcutaneous tumors
[3,4].
Musculosketetal involvement
Musculosketelal features of sarcoidosis include joint effu-
sions, joint pain, and, rarely, osseous involvement. Arthri-
tis has been reported in 15% to 58% of children with
sarcoidosis [4,5,11]. The arthritis of childhood sarcoidosis
is characterized by boggy tenosynovitis with relatively
painless effusion and good range of movement with often
no overlying erythema of the skin [46]. Multiple joints of
both the upper and lower extremities are involved. Radio-
graphic evidence of joint erosions or juxtaarticular oste-
oporosis is usually absent. Sarcoid arthritis can be
confused with juvenile rheumatoid arthritis (JRA) in
young children. Bone involvement is rarely noted in chil-
dren with sarcoidosis [15]. Symptomatic muscle involve-
ment is unusual both in adults and children.
Renal involvement
Renal involvement occurs infrequently in children with
sarcoidosis [11,15,47]. This is often related to hypercal-
cemia and hypercalciuria or less frequently to infiltration
of renal tissues with sarcoid granulomas [9,11,47]. The
clinical manifestations in reported cases of renal granulo-
matous sarcoidosis include proteinuria, leucocyturia,
hematuria, concentration defect, hypertension, membra-
nous nephropathy, interstitial nephritis, and renal failure
[48,49]. In a previous review, decreased creatinine clear-
ance was found in more than 60% of children with sar-
coidosis, although other evidence of renal dysfunction,
such as abnormal urinalysis results and elevated blood
urea nitrogen and serum creatinine values, were found in
less than 40% of children [11].
Skin rash in a 12-year-old female with sarcoidosis: Both  lower extremities showing elevated, diffuse purplish-colored  nodular and scaly rash Figure 3
Skin rash in a 12-year-old female with sarcoidosis: 
Both lower extremities showing elevated, diffuse 
purplish-colored nodular and scaly rash.Pediatric Rheumatology 2008, 6:16 http://www.ped-rheum.com/content/6/1/16
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Derangement in calcium metabolism manifesting as
hypercalcemia and/or hypercalciuria, occurs in up to 30%
of children, and can be associated with nephrocalcinosis
and nephrolithiasis [4,11,48]. In vitro experiments of cul-
tured alveolar macrophages from patients with sarcoido-
sis and of homogenized sarcoid lymph node tissue have
demonstrated that the sarcoid macrophage is able to syn-
thesize 1,25-dihydroxyvitamin D via 25-hydroxyvitamin
D3-1-alpha hydroxylating activity. The excess circulating
1,25-dihydroxyvitamin D produced extrarenally by the
granulomas causes increased intestinal absorption of cal-
cium, enhanced bone resorption, and resultant hypercal-
ciuria, with or without hypercalcemia [50].
Other organ systems
Parotid gland enlargement is a frequent finding in chil-
dren with sarcoidosis, especially the early onset type [6].
Sarcoidosis involving the heart has been well-docu-
mented in adults but rarely in children [6,10]. Clinical
manifestations of sarcoid cardiac disease may be varied
and include heart block, cardiomyopathy, or ventricular
arrhythmias. Vasculitis associated with sarcoidosis is unu-
sual but has been reported [3]. The majority of reports cite
involvement of small- to medium-size vessels contiguous
to diseased tissue, although large-vessel vasculitis associ-
ated with abdominal aortic aneurysm has been described
[3,51]. Involvement of the central nervous system disease,
although common in adults, are rare in children [52].
Early-onset childhood sarcoidosis and Blau 
syndrome
Early-onset childhood sarcoidosis, i.e., with onset in the
first 5 years of life differs from sarcoidosis in older chil-
dren and adults and often poses a diagnostic challenge to
the clinician [5,6,10,15]. Typically presenting in the first
year of life [10], patients with early-onset disease exhibit
unique clinical features characterized by the triad of
arthritis, rash, and uveitis. [5,6] Hilar lymphadenopathy,
the leading feature of late-onset forms [15], is rare in
early-onset sarcoidosis [5]. Uveitis, which occurs in about
in more than half the children with early-onset sarcodio-
sis, is relatively less common in patients with later onset
[6].
In 1985, Edward Blau described families with autosomal
dominant granulomatous disease demonstrating the clas-
sic triad of arthritis, dermatitis, and uveitis, an identical
phenotype to early-onset sarcoidosis [53]. Recent data
suggests that early-onset sarcoidosis and Blau syndrome
likely represent the same disease since both entities share
genetic mutations in the NOD2 (nucleotide binding oli-
gomerization domain 2), also referred to as capsule
recruitment domain family member 15 (CARD15) in 50–
90% of cases [54]. This finding has led some experts to
propose the term "pediatric granulomatous arthritis" to
describe both disorders [55]. Although clinical similarities
between Blau syndrome and sarcoidosis suggest genetic
homogeneity between them, a study by Rybicki and col-
leagues [56] found no linkage of sarcoidosis to the Blau
syndrome locus. Therefore, Blau gene has no major effect
on sarcoidosis susceptibility.
Early-onset sarcoidosis may be overlooked due to its sim-
ilarity to systemic-onset JRA [45]. Both entities may be
associated with systemic manifestations such as fever,
weight loss, and fatigue. Skin changes, however, may help
to distinguish between the two diseases at the onset. The
rash of JRA is pink, evanescent, and macular, whereas the
rash of sarcoidosis is classically a papule or a plaque with
scaling [5]. Arthritis of sarcoidosis is characterized by
painless boggy effusions of the synovium without limita-
tion of range of movement [5,46]. However, painful,
destructive polyarthritis with functional impairment
indistinguishable from that associated with JRA has been
described in early-onset sarcoidosis [6].
Diagnosis
There is no laboratory test diagnostic of sarcoidosis. Lab-
oratory evaluation may reveal elevated erythrocyte sedi-
mentation rate (ESR) or other acute phase reactants.
Anemia, leukopenia, and eosinophilia are commonly
seen on blood counts [4]. Immunological abnormalities
include hypergammaglobulinemia and impaired delayed
hypersensitivity on skin testing [1]. Hypercalcemia and/or
hypercalciuria may be found [9,11,15,47]. The serum
level of angiotensin-converting enzyme (ACE) is elevated
in over 50% of children with late-onset sarcoidosis
[4,57,58], but the test is not specific for sarcoidosis, and
many other disorders may be similarly associated with
increased serum ACE activity [3].
The source of serum ACE in sarcoidosis is believed to be
epitheloid cells in granulomata. ACE serum levels have
been shown to be useful in diagnosing sarcoidosis and
following disease activity and the effect of therapy in older
children with sarcoidosis [57,58]. Reference values for
serum ACE is age-dependent and healthy children have
ACE levels that are 40–50% higher than in adults [58].
Chest radiograph is very useful and may reveal bilateral
hilar adenopathy [4,42]. Because alveolitis precedes gran-
uloma formation in the lungs and is the earliest sign of
activity in pulmonary sarcoidosis, bronchoalveolar lavage
(BAL) performed through a flexible fiberoptic broncho-
scope has been used to assess that activity. [1,2] BAL typi-
cally demonstrates an increased number of lymphocytes,
most of which are activated helper-inducer T lym-
phocytes, which can cause the CD4/CD8 ratio to be high
[1,2]. However, in children BAL lymphocytosis does not
correlate with disease activity, treatment response or prog-Pediatric Rheumatology 2008, 6:16 http://www.ped-rheum.com/content/6/1/16
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nosis [59]. Therefore, serial BAL is not routinely recom-
mended in pulmonary sarcoidosis in children [9]. High-
resolution chest computed tomography (CT) can be help-
ful in delineating the extent of parenchymal disease and
hilar adenopathy. Although fibrotic lung disease is a rare
consequence of childhood sarcoidosis, follow-up with
pulmonary function tests (PFTs) is useful in detecting it.
Other studies such as gallium-scan, have not proven to
have clear prognostic benefits [3]. Another emerging tool
that is been used mainly in detecting metastatic cancer is
positron emession tomography (PET scan). A recent study
determined that PET scan does not allow differentiation
of interstitial pulmonary fibrosis (IPF) from a non-IPF
pulmonary diseases including sarcoidosis [60].
The diagnosis of sarcoidosis is confirmed by demonstrat-
ing a typical noncaseating epithelioid cell granuloma on a
biopsy specimen [61] (Figure 4). To further support the
diagnosis of sarcoidosis, infectious granulomatous condi-
tions (such as histoplasmosis, blastomycosis, and tuber-
culosis) must be excluded by special stains and cultures
[1,3]. The preferred non-invasive sites of biopsy in chil-
dren include peripheral lymph node, skin lesion, enlarged
salivary glands or lacrimal gland and conjunctival nodule.
Other potential sites for tissue biopsy include the bone,
bone marrow, liver, and lungs. The histopathological
findings noted in sarcoidosis have been observed in a
number of other disorders, such as tuberculosis, leprosy,
Sjogren syndrome, Behcet disease and berylliosis [1,9,61].
Occasionally, sarcoidosis may present initially as fever of
unknown origin (FUO) and localized bone pains, mim-
icking a number of infectious, inflammatory, and neo-
plastic processes. In such cases, magnetic resonance
imaging (MRI) may reveal multifocal small nodular
lesions within the marrow and help localize lesions for
diagnostic exploration [62].
Differential diagnosis
The differential diagnosis depends largely on the clinical
presentation of sarcoidosis [15]. It is critical to exclude
granulomatous pulmonary infections, especially those
caused by mycobacteria and fungi [3]. Exclude neoplastic
diseases, such as lymphoma, in cases with hilar adenopa-
thy. Hypercalcemia in sarcoidosis may mimic metabolic
disorders, such as primary hyperparathyroidism [3,15].
Early-onset sarcoidosis is often misdiagnosed as systemic-
onset JRA [45]. Rarely, severe symptomatic bone marrow
involvement may mimic a number of infectious and neo-
plastic disorders [62].
Treatment
The current therapy of choice for childhood sarcoidosis
with multisystem involvement is corticosteroids
[4,7,9,15,63]. Dose and duration of therapy must often be
individualized. Oral prednisone or prednisolone is usu-
ally initiated at 1–2 mg/kg/d for 4–8 weeks as induction
treatment [15,63]. This treatment is continued until the
clinical manifestations of the disease resolve or show sig-
nificant improvement. The steroid dosage is slowly
tapered in treatment responders over a period of 2–3
months to an appropriate maintenance dose (i.e., the low-
est dose that controls activity of the disease, typically 10–
15 mg per day as a once daily regimen) [63]. Depending
on which organs are involved and on the activity of the
disease, maintenance treatment is usually required for at
least 6 months for most age groups and then tapered if
possible [64]. Asymptomatic patients with isolated bilat-
eral hilar adenopathy may not need systemic steroid ther-
apy [64].
Some patients may relapse, either during steroid taper or
after discontinuation of the drug. In such cases, steroid
treatment should be restarted with a dosage similar to that
used in the induction treatment [65]. Few patients are
steroid-dependent and need long-term treatment with rel-
atively high doses to achieve satisfactory responses. In
such cases, serious complications due to chronic corticos-
teroid therapy, such as growth failure and bone disease,
may occur [3]. Moreover, a subset of patients with persist-
ent active or progressive sarcoidosis may be unresponsive
to corticosteroids; therefore, alternative agents are needed
[3,56,60,61].
Other immunosuppressive agents, especially low-dose
methotrexate (MTX) have been used to treat adult patients
with sarcoidosis who have steroid-resistant disease or in
those with unacceptable adverse effects from glucocorti-
Pathology of sarcoidosis: Skin biopsy specimen from the rash  in figure 3, revealing intradermal well-circumscribed, nonca- seating epitheloid granulomata with typical multinucleated  giant cells Figure 4
Pathology of sarcoidosis: Skin biopsy specimen from 
the rash in figure 3, revealing intradermal well-cir-
cumscribed, noncaseating epitheloid granulomata 
with typical multinucleated giant cells.Pediatric Rheumatology 2008, 6:16 http://www.ped-rheum.com/content/6/1/16
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coids with good success [64]. In 1997, Gedalia and col-
leagues [65] described their experience with 6 months of
low-dose oral MTX following a strict protocol in 7 chil-
dren with biopsy-proven sarcoidosis. Corticosteroids were
used for the first 6 weeks only in 6 of 7 cases. They were
treated with low-dose MTX for 1 year, and the clinical
response was scored using a composite of the various
symptoms encountered. MTX therapy resulted in
improvement in clinical symptom score and decreased
mean daily steroid dosage. Additionally, parallel
decreases in the ESR and the mean serum ACE concentra-
tions were observed. No adverse effects occurred in these
patients, all of whom received folate supplementation. In
this study, MTX administered orally in low doses in child-
hood sarcoidosis was effective, safe, and had steroid-spar-
ing properties [65]. However, because of significant
concerns regarding the risk of long-term adverse effects of
MTX therapy and lack of a randomized controlled trial,
some experts have questioned the therapeutic index of
MTX for corticosteroid-resistant sarcoidosis in children.
Liver biopsy performed after a cumulative MTX dose of 1–
1.5 g has been proposed to monitor liver toxicity. [3] MTX
toxicity can be minimized by the use of folic or folinic
acid. More recently a randomized trial of MTX in 24 adult
patients with sarcoidosis by Baughman and colleagues
had shown that MTX has steroid sparing property [66].
Alternative immunosuppressive agents, such as azathio-
prine, cyclophosphamide, chlorambucil, and
cyclosporine, have been tried in adult cases of sarcoidosis
with questionable efficacy [67]. The high toxicity profile
of these agents, including an increased risk of lymphopro-
liferative disorders and carcinomas, has limited their use
to patients with severe disease refractory to other agents.
Successful steroid-sparing treatment with mycophenolate
mofetil was described in an adolescent with renal-limited
sarcoidosis complicated by renal failure [67]. Novel treat-
ment strategies for sarcoidosis have been developed
including the use of TNF-alpha inhibitors, such as inflixi-
mab [67]. Anecdotal case reports about the use of inflixi-
mab in renal sarcoidosis exist in the pediatric literature
[68].
Prognosis
The prognosis and natural history of sarcoidosis in chil-
dren is unclear because of the rarity of the disease and the
small number of reported series. [4,11,69,70] However,
the overall prognosis of childhood sarcoidosis is reported
as good compared with the prognosis for adults, with
most children experiencing considerable improvement in
clinical manifestations, chest radiograph findings, and
pulmonary function test results [11].
In one series, Marcille et al [70] performed a follow-up
study on 19 patients in whom sarcoidosis had been diag-
nosed in childhood. The mean follow-up period was 21
years (range 8–35 y). Seven patients (37%) had persistent
abnormalities on chest radiograph, 68% had impaired
lung function, and 63% had abnormal findings on
echocardiography [70]. In another series from the Univer-
sity of North Carolina, most patients improved; however,
40% still were symptomatic and 35% had physical abnor-
malities after an average follow-up of 5 years [11].
Sarcoidosis in very young children with involvement of
the eyes, joints and skin have a guarded prognosis with
the likelihood of a chronic progressive course [5,6]; 80–
100% of these children develop residua of uveitis, polyar-
thritis, and other organ involvement [6]. Another case
series comprising 6 patients with early-onset sarcoidosis
and a long follow-up with a mean of 14 years (range 0–23
y) reported on the severe outcome of the disease, includ-
ing blindness (4 patients), growth retardation (3
patients), cardiac involvement (2 patients), renal failure
(1 patient), and even death (1 patient) [10]. Progressive
ocular disease may produce severe disability with second-
ary glaucoma resulting in blindness. Currently, longitudi-
nal clinical assessment focusing on the severity of the
disease in affected organs remains the best approach to
prognosis. Large follow-up studies are needed to better
understand long-term prognosis in childhood sarcoido-
sis.
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